Rp. Croft et al., Incidence rates of acute nerve function impairment in leprosy: a prospective cohort analysis after 24 months (The Bangladesh Acute Nerve Damage Study), LEPROSY REV, 71(1), 2000, pp. 18-33
In this paper, the incidence rates and cumulative incidence of nerve functi
on impairment (NFI) and leprosy reactions over 24 months follow-up of the p
rospective cohort of 2664 new leprosy cases are presented. Graphs showing t
he cumulative incidence of NFI relative to time since registration are pres
ented. Hazard ratios (HRs) for the development of NFI for four variables ar
e given. The majority of patients who developed NFI after registration did
so in the first year (67% of multibacillary (MB) patients, and 91% of pauci
bacillary (PB) patients who developed NFI). Thirty-three percent of all MB
patients who developed NFI after registration did so in the second year of
follow-up. No PB patients developed NFI for the first time in the last 6 mo
nths of follow-up. However, seven NFI events occurred amongst PB patients i
n that period, amongst those who had already had one NFI event. The inciden
ce rate (IR) of NFI amongst MB patients was 24/100 person-years at risk (PY
AR), and amongst PB patients was 1.3/100 PYAR. The HR for the development o
f NFI amongst MB patients compared with PB patients was 16 using univariate
analysis. Amongst patients who had long-standing NFI present at registrati
on, the IR was 27/100 PYAR compared with 1.7/100 PYAR amongst those who did
not have long-standing NFI. The HR for developing acute NFI amongst those
with longstanding NFI present at registration compared with those without w
as 14 using univariate analysis. When multivariate regression analysis is a
pplied, the apparently significant univariate HRs for sex and age disappear
ed. The resultant multivariate HR for leprosy group is 8.8, and 6.1 for the
presence/absence of long-standing NFI at registration. In all, 142/166 (86
%) of all new NFI events were silent, underlining the need for regular nerv
e function testing. IRs are presented for the four 6-month periods of the 2
4-month follow-up. They show a clear stepwise reduction over the total peri
od. The IRs amongst MB patients and those with long-standing NFI present at
registration are very high at 34 and 41/100 PYAR, respectively, for the fi
rst 6 months of follow-up. Even during the final 6-month period, the IR is
maintained at a moderately high level (18 and 15/100 PYAR, respectively).